Title page

Title: The time is ripe to harmonize global acute febrile illness etiologic investigations

Running title: Harmonization of acute febrile illness investigations methods

Article category: Letter

Author names & institutional affiliations: José Moreira[1,2], B. Leticia Fernando-Carballo[3], Camille Escadafal[3], Sabine Dittrich[3,4], Patrícia Brasil[1], André M Siqueira[1]

Affiliations:

1.Laboratório de Pesquisa Clínica em Doenças Febris Agudas, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

2. Instituto Nacional de Cardiologia, Departamento de Ensino e Pesquisa, Rio de Janeiro, Brazil

3. Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland

4. Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

Corresponding author: José Moreira MD Ph.D; e-mail: jose.moreira@ini.fiocruz.br; telephone number: +55 (21) 97035-8843; Laboratório de Pesquisa Clínica em Doenças Febris Agudas, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Av. Brasil, 4365 – Manguinhos, Rio de Janeiro, Brazil, CEP: 21040-360; Twitter: @j_moreira_

Keywords: Antipyretic therapy; Fever; Acute febrile illness; Dipyrone; Methodology

Abstract

Acute febrile illness (AFI) is common for people seeking care globally and represents a spectrum of infectious and non-infectious etiologies with significant geographical variations. However, AFI research follows a heterogeneous methodology and reporting, making it challenging for individual fever studies interpretation and comparison and thus generating evidence-based decisions. Herein, we aim to conduct a pilot study investigating the impact of considering different case definitions of fever as inclusion criteria among febrile patients attending two Emergency Departments (ED) in Rio de Janeiro, Brazil, from October 28, 2018, to March 29, 2019. Secondarily, we explored the impact of the recent use of antipyretics in measured temperature at the arrival of the EDs. A prospective study was conducted, and we screened all consecutive non-severe patients who presented to the EDs. The inclusion criterion was the self-report of fever regardless of the temperature measured. A logistic regression model was built to investigate the factors associated with a febrile presentation at the arrival of EDs. We triaged 1551 subjects, and 374 [24.1% (95% CI 22-26)] had a history of fever, of whom 248 (66.3%), 115 (30.7%), and 11 (2.9%) had a temperature <37.5°C, ≥ 37.5 °C, and no temperature measurement registered at arrival, respectively. 198/374 (53%) had a suspicion of infection, and the site of infection varied according to the height of temperate at presentation. The antibiotic prescription was more likely in those who had a temperature ≥ 37.5 °C compared to those with a temperature <37.5°C [crude OR: 2 (95% 1.1-3.5)]. 249/374 (66.6%) subjects reported self-administering an antipyretic within 2h [IQR 2-6] before EDs. Recent antipyretic uptake did not influence the measured temperature at presentation. In conclusion, we suggest harmonizing the case definition of fever in AFI research for a history of fever regardless of temperature cut-off would enable a complete picture of the different clinical fever phenotypes, thus improving our understanding of the global burden of febrile illness.

Text

Acute febrile illness (AFI) is a common reason for people seeking care and represents a range of infectious and non-infectious diseases, with wide variation by region of the globe [1]. AFI investigations aim to inform national and subregional treatment guidelines about empirical and pathogen-specific treatment algorithms to prioritize interventions and funding. Several AFI investigations have been conducted primarily in Southeast Asia, with few global initiatives in resource-constrained countries [2]. However, there is no standardized approach to conducting such studies, limiting the interpretation and comparability of study findings.

We were involved in a multinational project around fever host-biomarkers [3] and aimed to conduct a pilot study to inform the best criteria for our study site selection. We hypothesized that adopting a subjective or self-reported fever assessment as part of our inclusion criteria would increase the sensibility threshold for a broad array of febrile clinical phenotypes rather than specifying a cut-off value for fever. Another hypothesis was that the recent antipyretic intake would lower body temperature at the arrival of the Emergency Departments (EDs).

Here, we did a cross-sectional, study of patients presenting to two urban EDs (Unidade de Pronto Atendimento Manguinhos & Unidade de Pronto Atendimento Rocha Miranda) in Rio de Janeiro, Brazil, between October 28, 2018, and March 29, 2019. The study was conducted following the Declaration of Helsinki and the Brazilian National Ethics Research Committee and was approved in August 2018 (IRB approval no:70984617.9.0000.5262). We screened all consecutive non-severe patients who presented to the EDs over the study period and included those who reported fever ≤ 7 days regardless of temperature measured at the EDs. Research assistants collected prospectively detailed information and interviewed participants or the primary caregivers to obtain data about the demographics, main chief complaint, vital signs, history of fever, peak measured temperature before arrival at the EDs (temperature maximum), the measured temperature at the EDs, home administration of antipyretics,

type/dose/timing of last administration, and tests performed at the EDs. Discharge diagnosis and treatment received after discharge was retrospectively collected by reviewing electronic medical records. The attending physician proposed the discharge diagnosis (not involved in the study), and its appropriateness was not re-evaluated. We used the following definitions: fever was subjectively identified by the participant at arrival at the EDs; antipyretics are mostly nonprescription drugs that act on the fever physiologic pathway, inhibiting the release of pyrogenic cytokines and lowering the core body temperature, and those were self-administered by the participants before seeking emergency care; adults those aged ≥ 18 years at recruitment, and non-severe AFI was an illness that was codified as blue or green according to the Manchester Triage System at EDs, which does not require hospital admission. We measured the axillary temperature at triage and estimated the magnitude of defervescence, considering the highest measured self-reported temperature before EDs arrival (Tmax). Suspected infection was defined as the initiation of any antimicrobial after an EDs visit. We built a logistic regression model to investigate the factors associated with febrile presentation (i.e., temperature ≥ 37.5 °C) among patients attending the study sites. The primary outcome was to investigate the impact of considering different definitions of fever as inclusion criteria among febrile patients attending EDs.

During the study period, we triaged 1551 subjects, and 374 [24.1% (95% CI 22-26)] had a history of fever at arrival at the ED, corresponding to a cumulative incidence of fever at EDs of 24 per 100 triaged patients over the five months. These 374 febrile patients constitute our study population, of whom 248 (66.3%), 115 (30.7%), and 11 (2.9%) had a temperature < 37.5 °C, ≥ 37.5 °C, and no temperature measurement registered at arrival, respectively. The mean age was 30.6 [range: 0-84] years, adults (82.5%) and females (54.8%) predominated (Table). The median peak measured temperature before arrival at the ED was 38.8°C (38.0-39.0), and the median duration of fever was 1 [1-3] days.

Hundred ninety-eight febrile patients had a suspicion of infection, with upper respiratory tract infection (42.4%) followed by undifferentiated febrile illness (15.7%) and urinary tract infection (14.6%) were the primary febrile syndromes (Supplementary Figure 1). The most commonly prescribed antibiotic classes were beta-lactams (73/131, 55.7%), quinolones (23/131, 17.5%) and macrolides (16/131,12.2%). Patients who had temperature ≥ 37.5 °C at presentation were more likely to be diagnosed with an infection [76 (66%) *vs*. 116 (47%), crude OR: 2.2 (95% 1.4-3.5) and were prescribed antibiotic most frequently compared to those with temperature < 37.5 °C [54 (65%) *vs*. 75 (48%), crude OR: 2 (95% 1.1-3.5)].

The site of infection varied by the height of temperature mensurated at arrival at EDs (p<0.001). Patients who had a temperature < 37.5 °C at presentation were more likely to be diagnosed with upper respiratory (31.6%) and urinary infections (15.4%) (Supplementary Figure 3). The most frequently etiology diagnostics recorded in those with temperature < 37.5 °C at presentation were acute pharyngitis (20/248, 8%), followed by community-acquired gastroenteritis (19/248, 7.6%), uncomplicated urinary tract infection (16/248, 6.4%), cutaneous abscess (14/248, 5.6%), and community-acquired pneumonia (9/248, 3.6%).

In total, 249/374 (66.6% (95% 61.5-71.3)]) subjects reported self-administering an antipyretic at home within a median of 2h [IQR 2-6] before EDs admission (24.1% of the febrile subjects did not recall prior antipyretics intake). Dipyrone (72.2%) was the antipyretic drug most frequently administered, followed by acetaminophen (14.3%) and ibuprofen (6.3%). Most antipyretic takers consumed one class (85.9%), and the median number of doses taken was 2 [IQR 1-3]. Of these 249 subjects, 167/249 (67%) reported the last dose administered at a mean of 2 [2-5] hours before hospital presentation. Subjects who were treated with an antipyretic drug before arrival did not differ from untreated ones regarding the temperature at arrival at the ED visit (37 ± 0.99 *vs*. 36.8 ± 0.86, p = 0.20) or the documented

Tmax before the ED arrival (38.8 ± 0.79 *vs*. 38.4 ± 0.60, $p = 0.29$). In the model adjusted for other confounder variates (gender, age, heart rate, number of antipyretics administered, time-lapse since the last dose of antipyretics administered, time of fever onset, and prior antibiotic intake), the variable that was independently associated with a febrile presentation was the heart rate (adjusted OR: 1.035 [95% CI:1.005-1.067].

Our study suggests that considering a subjective/self-reported fever as an inclusion criterion rather than a specific fever cut-off value (i.e., ≥ 37.5 °C) for AFI etiologic investigation results in a more inclusive study population and account for the diversity of clinical fever phenotypes that are usually seen in clinical practice. Specifically, sixty-six percent of our cohort would not have been included if we restricted our inclusion criteria to a specific febrile cut-off, potentially impacting study recruiting and patient characterization. Almost half (47.8%) of febrile participants with temperature < 37.5 °C at presentation were prescribed at least one antibiotic, and their infections were mainly upper respiratory, justifying their inclusion in AFI studies. Next, our findings suggest that the ubiquitous administration of antipyretics (66.6%) observed in our setting did not influence the febrile presentation of patients attending the EDs evaluated.

We concur with others [2, 4] and argue that there is an urgent need to standardize AFI study protocols to make sure that we can compare results from different studies and pool their results to develop national, regional, or global burden of fever estimates. Such consensus in AFI research would allow better comparisons, translate evidence to practice, and inform treatment policy. A harmonized definition of fever would enable a more robust and consistent capture of different clinical phenotypes, including those conditions where overt fever occurs inconsistently, such as upper respiratory infections and uncomplicated urinary infections. Others [2] have suggested an adapted STROBE checklist for conducting and reporting AFI research.

In conclusion, we suggest harmonizing the case definition of fever in AFI research for a history of fever regardless of temperature cut-off would enable a complete picture of the different clinical fever phenotypes, thus improving our understanding of the global burden of febrile illness.

Author contributions

JM: writing original draft, visualization, conceptualization. BC: Review and editing. CE: Review and editing. SD: review, editing. PB: conceptualization, writing, editing, supervision. AS: conceptualization, writing, editing, supervision

Funding

The Biomarker for Fever-Diagnostic (BFF-Dx) study was funded by the Dutch, Australian and UK governments.

Transparency declaration

The authors have no conflict of interest to declare.

References

1. Moreira J, Bressan CS, Brasil P, Siqueira AM. Epidemiology of acute febrile illness in Latin America. Clin Microbiol Infect. 2018; 24(8):827-835.
2. Rhee C, Kharod GA, Schaad N et al. Global knowledge gaps in acute febrile illness etiologic investigations: a scoping review. PLoS Negl Trop Dis. 2019; 13(11): e0007792.
3. Escadafal C, Geis S, Siqueira AM, et al. Bacterial versus non-bacterial infections: a methodology to support use-case-driven product development of diagnostics. *BMJ Glob Health*. 2020; 5(10)e:003141.2.
4. Newton PN, Guerin PJ. Febrile illness mapping-much of the world without data and without evidence-based treatments. BMC Med. 2010; 18(1):287.

177 **Supplementary Tables**

178 Supplementary Table. Diagnosis, febrile syndrome, and antibiotic prescription in febrile
179 patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March
180 2019

181 **Supplementary Figures**

182 Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients
183 attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

184 Supplementary Figure 2. Variability in antibiotic prescription accordingly to the foci of
185 infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil,
186 October 2018-March 2019

187 Supplementary Figure 3. Foci of infection according to the height of temperature
188 mensurated at arrival in febrile patients attending Emergency departments in Rio de
189 Janeiro, Brazil, October 2018-March 2019

190 Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated
191 at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil,
192 October 2018-March 2019

193

194

195

196

197

198

Table. Baseline characteristics according to the height of temperature mensurated at arrival in febrile patients attending emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

	Total febrile population **N= 374**		**History of fever but temperature < 37.5 °C** **N= 248**	**History of fever and temperature ≥ 37.5 °C** **N= 115**	***p*-value**
Characteristics					
Demographics					
Age (years), mean (±SD)	31 (16)		32 (15)	28 (16)	**0.02**
Male, n- (%)	169 (45.2)		103 (41.5)	62 (53.9)	**0.02**
Temp at arrival, (°C), mean (±SD)	37.08 (0.9)		36.55 (0.5)	38.24 (0.6)	**<0.01**
Tmax (°C), mean (±SD)	38.7 (0.7)		38.7 (0.69)	38.95(0.9)	0.12
Days of fever, mean (±SD)	1.58 (17.4)		1.45 (21.2)	1.80 (3.2)	0.86
Degree of defervescence from Tmax, mean (±SD)	1.70 (1.13)		2.16 (0.86)	0.78 (1.04)	**<0.01**
Diagnosis and management					
Diagnostic testing – n (%)	76 (30.2)		42 (26.1)	32 (38.1)	0.05
Recent antibiotic use – n (%)	21 (12.2)		11 (9.6)	10 (18.9)	0.09
Recent antipyretic use – n (%)	249 (66.6)		169 (87.1)	76 (90.5)	0.42
Antibiotic prescription – n (%)	131 (53.0)		75 (47.8)	54 (65.1)	**0.01**

SD means standard deviation; Tmax higher temperature self-recorded at home before emergency department visit

Key messages

- Fever is a common reason to seek care in patients attending urban Emergency Departments in Rio de Janeiro, Brazil
- Suspicion of infection is the underlying cause of fever in 53% of the febrile subjects, and the respiratory source is the main focus of infection
- The use of antipyretics among febrile patients attending urban Emergency Departments in Rio de Janeiro is ubiquitous, and dipyrone is the antipyretic of choice in our population. However, such use did not influence febrile presentation in Emergency Departments
- Our findings are essential for designing fever etiology and question the value of adopting specific temperature criteria for fever at enrollment, as in many fever studies. We believe that a history of fever as part of inclusion criteria is a good surrogate of unwellness and might be incorporated systematically in future fever studies.

Appendix Table of Contents

This supplementary material has been provided by the authors to give readers additional information about their work.

Supplementary Tables

- Supplementary Table. Diagnosis, febrile syndrome, and antibiotic prescription in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019

Supplementary Figures

- Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019
- Supplementary Figure 2. Variability in antibiotic prescription accordingly to the foci of infection in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019
- Supplementary Figure 3. Foci of infection according to the height of temperature mensurated at arrival in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019
- Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated at arrival in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019

Supplementary Figure 1. Antibiotic class according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019



AUFI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Supplementary Figure 2. Variability in antibiotic prescription according to the foci of infection in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019



AUFI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Supplementary Figure 3. Foci of infection according to the height of temperature mensurated at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019



AUFI stands for acute undifferentiated febrile illness; LRTI lower respiratory tract infection; SSTI skin and soft tissue infection; URTI upper respiratory tract infection; and UTI urinary tract infection

Supplementary Figure 4. Antibiotic class according to the height of temperature mensurated at arrival in febrile patients attending Emergency departments in Rio de Janeiro, Brazil, October 2018-March 2019



Supplementary Table. Diagnosis, febrile syndrome, and antibiotic prescription in febrile patients attending Emergency Departments in Rio de Janeiro, Brazil, October 2018-March 2019

Presumed diagnosis by febrile syndrome	Number of presentations n/N (%)	Number of patients receiving an antibiotic prescription n/N (%)
Gastrointestinal		
Gastroenteritis	16/17 (94.11)	7/16 (43.75)
Gastritis	1/17 (5.88)	1/1 (100)
Upper respiratory tract infection		
Acute tonsillitis	34/84 (40.47)	34/34 (100)
Acute pharyngitis	22/84 (26.19)	5/22 (22.72)
Acute sinusitis	8/84 (9.52)	6/8 (75)
Common cold	5/84 (5.95)	0/5 (0)
Other upper respiratory tract infections	15/84 (17.85)	9/15 (60)
Lower respiratory tract infection		
Acute bronchitis and COPD exacerbations	3/17 (17.64)	2/3 (66.66)
Community-acquired pneumonia	9/17 (52.94)	8/9 (88.88)
Influenza	2/17 (11.76)	0/2 (0)
Other lower respiratory tract infections	3/17 (17.64)	3/3 (100)
Skin and soft tissue infection		
Cellulitis and abscesses	14/19 (73.68)	14/14 (100)
Other infection of the skin and soft tissue	4/19 (21.05)	4/4 (100)
Bacterial skin infection	1/19 (5.26)	1/1 (100)
Urinary tract infection		
Uncomplicated cystitis & pyelonephritis	28/29 (96.55)	25/28 (89.28)
Other urinary infection	1/29 (3.44)	1/1 (100)
Acute undifferentiated febrile illness		
Arboviruses	5/30 (16.66)	0/5 (0)
Unspecified febrile illness	6/30 (20)	4/6 (66.66)
Leptospirosis	2/30 (6.66)	2/2 (100)
Unspecified viral infection	15/30 (50)	1/15 (6.66)
Other	1/30 (3.33)	1/1 (100)

COPD stands for chronic obstructive pulmonary disease